The Technical Analyst
Orgenesis Inc [ORGS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Orgenesis Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.48% $0.500
America/New_York / 26 apr 2024 @ 11:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.18 mill |
| EPS: | -1.910 |
| P/E: | -0.260 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 34.34 mill |
| Avg Daily Volume: | 0.242 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.260 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.260 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.395 - 0.605 ( +/- 20.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Miller Victor | Sell | 25 000 | Stock Option (Right to Buy) |
| 2024-04-01 | Miller Victor | Buy | 25 000 | Common Stock |
| 2024-02-01 | Safier Jacob | Buy | 10 100 | Common Stock (par value $0.01) |
| 2024-01-31 | Safier Jacob | Buy | 5 000 | Common Stock (par value $0.01) |
| 2024-01-30 | Safier Jacob | Buy | 25 000 | Common Stock (par value $0.01) |
| INSIDER POWER |
|---|
| 93.70 |
| Last 93 transactions |
| Buy: 2 511 105 | Sell: 463 608 |
Forecast:
13:36 - $0.507
Live Trading Signals (every 1 min)
Forecast
1: 12:06 - $0.501
Forecast 2: 12:56 - $0.505
Forecast 3: 13:36 - $0.507
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.500 (-2.48% ) |
| Volume | 0.0215 mill |
| Avg. Vol. | 0.242 mill |
| % of Avg. Vol | 8.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ORGS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ORGS
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Latest Press Releases
2024-04-15 17:07:00 - Press Release
Orgenesis Provides Year End Business Update
M ajor transformation underway commencing with recent acquisition reasserting full ownership and control over octomera
2024-04-10 12:00:00 - Press Release
Germfree And Orgenesis Announce Asset Purchase And Strategic Partnership Intended To Revolutionize Cell And Gene Therapy Through Decentralized Production And Global Accessibility
Ormond beach, fla. and germantown, md., april 10, 2024 (globe newswire) -- germfree, a leading innovator in modular cleanroom infrastructure and services, and orgenesis inc. (nasdaq: orgs), a global leader in decentralizing cell and gene therapies (cgts), today announced an asset purchase and strategic partnership aimed at advancing orgenesis' therapeutic programs and its suite of product development and gmp cell processing services. the collaboration's goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.
2024-03-18 08:30:00 - Press Release
Vered Caplan, Ceo Of Orgenesis, To Present At The Bioprocessing Summit Europe Conference
Germantown, md., march 18, 2024 (globe newswire) -- orgenesis inc. (nasdaq:orgs) (“orgenesis” or the “company”), a global leader in decentralizing cell and gene therapies (cgts), today announced that its ceo, vered caplan, will be presenting at the upcoming bioprocessing summit europe. the conference, renowned for gathering leading professionals to advance the manufacturing and quality control of biological and genetic therapies, will take place in barcelona from march 19th to 21st, 2024.
2024-03-13 08:30:00 - Press Release
Orgenesis Consortium Awarded €1.5m Eur Grant From The Walloon Government In Belgium For Exofasttrack Project Dedicated To Accelerated Development Of Multiple Therapeutic Exosomes
Germantown, md., march 13, 2024 (globe newswire) -- orgenesis inc. (nasdaq:orgs) (“orgenesis” or the “company”), a global leader in decentralizing cell and gene therapies (cgts), today announced that the company has been awarded a €1.5 million grant from the walloon government in belgium for its exofasttrack project focused on manufacturing, loading, analytical methods and quality control of therapeutic exosomes. consortium members include: orgenesis, cilyx, cmmi, convexyo, exo biologics, exoxpert, genflow biosciences, livedrop, ulb, umons and xomexbio. this grant is the second such project awarded to an orgenesis consortium by the walloon government partnership, atmp-partenariat d'innovation technologique (atmp-pit), in collaboration with biowin, the health cluster of wallonia, and the public service of wallonia.
2024-03-04 08:30:00 - Press Release
Orgenesis Inc. Announces $2.3 Million Private Placement
Germantown, md., march 04, 2024 (globe newswire) -- orgenesis inc. (nasdaq: orgs) (“orgenesis” or the “company”), a global leader in decentralized cell and gene therapies (cgts), announced today that it has entered into a definitive securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the company's common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants. the warrants are exercisable immediately and expire five years from the date of issuance...
Latest News
2024-03-18 08:30:00 - GlobeNewsWire
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe. The conference, renowned for gathering leading professionals to advance the manufacturing and quality control of biological and genetic therapies, will take place in Barcelona from March 19th to 21st, 2024.
2023-08-10 08:30:00 - GlobeNewsWire
Orgenesis Schedules Second Quarter 2023 Business Update Conference Call
GERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 11, 2023, to discuss the company's corporate progress and other developments.
2023-05-19 08:30:00 - GlobeNewsWire
Orgenesis to Participate in Benchmark's 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark Company's 3rd Annual Healthcare House Call Virtual 1x1 Conference, which will be held on Tuesday, May 23, 2023.
2023-03-17 09:00:00 - GlobeNewsWire
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call
GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, March 21, 2023, to discuss the company's corporate progress and other developments.
2022-11-23 00:27:16 - 24/7 Wall Street
New Dimensions Trading Discloses Large Position in ORGS / Orgenesis
Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).
2022-11-13 21:29:02 - Seeking Alpha
Orgenesis (ORGS) Q3 2022 Earnings Call Transcript
Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Orgenesis Third Quarter 2022 Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Mr.
2022-11-10 08:30:00 - GlobeNewsWire
Orgenesis Schedules Third Quarter 2022 Business Update Conference Call
GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company's corporate progress and other developments.
2022-08-16 17:22:10 - Seeking Alpha
Orgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call Transcript
Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithinger – Chief Financial Officer Conference Call Participants Bruce Jackson – The Benchmark Company Operator Good day, ladies and gentlemen, and welcome to the Orgenesis Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, David Waldman from Investor Relations.
2022-08-16 11:59:47 - Proactive Investors
Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platform
Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a $10 million loan from investment firm Metalmark Capital Partners for Orgenesis (NASDAQ:ORGS)' point of care (POCare) services business for treating patients.
2022-08-15 09:14:00 - GlobeNewsWire
Orgenesis Schedules Second Quarter 2022 Business Update Conference Call
GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company's corporate progress and other developments.